Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and raises the price target from $22 to $24.
June 20, 2023 | 5:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Catalyst Pharmaceuticals and raises the price target from $22 to $24.
The news of Truist Securities maintaining a Buy rating and raising the price target for Catalyst Pharmaceuticals (CPRX) from $22 to $24 indicates a positive outlook for the stock. This could lead to increased investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100